Caribou Biosciences, Inc. (NASDAQ:CRBU) Shares Purchased by Barclays PLC

Barclays PLC increased its holdings in shares of Caribou Biosciences, Inc. (NASDAQ:CRBU) by 122.4% in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 129,839 shares of the company’s stock after purchasing an additional 71,463 shares during the period. Barclays PLC owned 0.14% of Caribou Biosciences worth $255,000 as of its most recent SEC filing.

A number of other large investors have also recently bought and sold shares of the business. The Manufacturers Life Insurance Company raised its position in Caribou Biosciences by 16.8% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 36,489 shares of the company’s stock worth $60,000 after buying an additional 5,244 shares during the last quarter. China Universal Asset Management Co. Ltd. raised its position in Caribou Biosciences by 63.8% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 17,380 shares of the company’s stock worth $34,000 after buying an additional 6,768 shares during the last quarter. Erste Asset Management GmbH purchased a new position in Caribou Biosciences during the 3rd quarter worth $28,000. American Century Companies Inc. raised its position in Caribou Biosciences by 15.2% during the 2nd quarter. American Century Companies Inc. now owns 125,029 shares of the company’s stock worth $205,000 after buying an additional 16,530 shares during the last quarter. Finally, AQR Capital Management LLC purchased a new position in shares of Caribou Biosciences in the 2nd quarter valued at about $30,000. Institutional investors and hedge funds own 77.51% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities analysts have recently issued reports on CRBU shares. Citigroup cut their price target on shares of Caribou Biosciences from $30.00 to $6.00 and set a “buy” rating for the company in a report on Tuesday, November 26th. HC Wainwright reiterated a “buy” rating and issued a $9.00 price target on shares of Caribou Biosciences in a report on Friday, November 15th. Four investment analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock presently has an average rating of “Buy” and a consensus price target of $10.20.

Caribou Biosciences Trading Up 2.4 %

Shares of NASDAQ CRBU opened at $1.72 on Monday. The stock has a market cap of $155.75 million, a price-to-earnings ratio of -1.04 and a beta of 2.27. Caribou Biosciences, Inc. has a 52 week low of $1.50 and a 52 week high of $8.33. The company’s 50-day moving average price is $2.03 and its 200 day moving average price is $2.00.

Caribou Biosciences (NASDAQ:CRBU) last released its quarterly earnings results on Wednesday, November 6th. The company reported ($0.38) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.44) by $0.06. Caribou Biosciences had a negative net margin of 1,290.81% and a negative return on equity of 45.46%. The company had revenue of $2.02 million for the quarter, compared to analysts’ expectations of $3.37 million. As a group, research analysts expect that Caribou Biosciences, Inc. will post -1.64 earnings per share for the current year.

Caribou Biosciences Profile

Caribou Biosciences, Inc, a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies in the United States and internationally. Its lead product candidate is CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma.